Alliance Reports Results from First Randomized Trial of a Radiopharmaceutical in Kidney Cancer
RadiCaL study results show adding bone-targeting radium-223 to cabozantinib does not improve symptomatic skeletal-related events, highlighting the value of current standard treatments to optimize bone health for patients with bone metastases

August 17, 2026 - Results from the Alliance for Clinical Trials in Oncology’s Phase II RadiCaL trial (Alliance A031801), the first randomized s

• Read more

Alliance SOLARIS Trial: Vitamin D3 Fails to Boost Colorectal Cancer Survival

August 13, 2026 - For patients with advanced colorectal cancer, adding high-dose vitamin D₃ to standard first-line treatment does not improve progression-free survival, according to the results from the Phase III SOLARIS trial (Alliance A021703) published in the Journal of the American Medical Association.

Experimental evidence has suggested that vitamin D may have antineoplastic activity, including effe

• Read more

July Media Mentions: Sharing News from the Alliance in the Media

August 4, 2026 - The media relations efforts from Alliance staff and researchers are designed to alert the public about the vital work happening across our network. When we share stories about clinical trial results, scientific milestones, or investigator achievements, we are showcasing the real-world progress you help make possible.

More than just news mentions, these media stories serve a crucial purpose for the o

• Read more